215 related articles for article (PubMed ID: 26222184)
1. Focus on 16p13.3 Locus in Colon Cancer.
Mampaey E; Fieuw A; Van Laethem T; Ferdinande L; Claes K; Ceelen W; Van Nieuwenhove Y; Pattyn P; De Man M; De Ruyck K; Van Roy N; Geboes K; Laurent S
PLoS One; 2015; 10(7):e0131421. PubMed ID: 26222184
[TBL] [Abstract][Full Text] [Related]
2. Deletion of chromosome 4q predicts outcome in stage II colon cancer patients.
Brosens RP; Belt EJ; Haan JC; Buffart TE; Carvalho B; Grabsch H; Quirke P; Cuesta MA; Engel AF; Ylstra B; Meijer GA
Anal Cell Pathol (Amst); 2010; 33(2):95-104. PubMed ID: 20966546
[TBL] [Abstract][Full Text] [Related]
3. Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients.
van den Broek E; Krijgsman O; Sie D; Tijssen M; Mongera S; van de Wiel MA; Belt EJ; den Uil SH; Bril H; Stockmann HB; Ylstra B; Carvalho B; Meijer GA; Fijneman RJ
Oncotarget; 2016 Nov; 7(45):73876-73887. PubMed ID: 27729614
[TBL] [Abstract][Full Text] [Related]
4. Candidate driver genes in focal chromosomal aberrations of stage II colon cancer.
Brosens RP; Haan JC; Carvalho B; Rustenburg F; Grabsch H; Quirke P; Engel AF; Cuesta MA; Maughan N; Flens M; Meijer GA; Ylstra B
J Pathol; 2010 Aug; 221(4):411-24. PubMed ID: 20593488
[TBL] [Abstract][Full Text] [Related]
5. Deletion of chromosome 4q predicts outcome in stage II colon cancer patients.
Brosens RP; Belt EJ; Haan JC; Buffart TE; Carvalho B; Grabsch H; Quirke P; Cuesta MA; Engel AF; Ylstra B; Meijer GA
Cell Oncol (Dordr); 2011 Jun; 34(3):215-23. PubMed ID: 21717218
[TBL] [Abstract][Full Text] [Related]
6. Molecular predictors of survival after adjuvant chemotherapy for colon cancer.
Watanabe T; Wu TT; Catalano PJ; Ueki T; Satriano R; Haller DG; Benson AB; Hamilton SR
N Engl J Med; 2001 Apr; 344(16):1196-206. PubMed ID: 11309634
[TBL] [Abstract][Full Text] [Related]
7. Comparative genomic hybridization: comparison between esophageal squamous cell carcinoma and gastric cardia adenocarcinoma from a high-incidence area for both cancers in Henan, northern China.
Wang LD; Qin YR; Fan ZM; Kwong D; Guan XY; Tsao GS; Sham J; Li JL; Feng XS
Dis Esophagus; 2006; 19(6):459-67. PubMed ID: 17069589
[TBL] [Abstract][Full Text] [Related]
8. DNA copy number alterations, gene expression changes and disease-free survival in patients with colorectal cancer: a 10 year follow-up.
Bigagli E; De Filippo C; Castagnini C; Toti S; Acquadro F; Giudici F; Fazi M; Dolara P; Messerini L; Tonelli F; Luceri C
Cell Oncol (Dordr); 2016 Dec; 39(6):545-558. PubMed ID: 27709558
[TBL] [Abstract][Full Text] [Related]
9. Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma.
Patil MA; Gütgemann I; Zhang J; Ho C; Cheung ST; Ginzinger D; Li R; Dykema KJ; So S; Fan ST; Kakar S; Furge KA; Büttner R; Chen X
Carcinogenesis; 2005 Dec; 26(12):2050-7. PubMed ID: 16000397
[TBL] [Abstract][Full Text] [Related]
10. A copy number gain of the 6p arm is linked with advanced hepatocellular carcinoma: an array-based comparative genomic hybridization study.
Chochi Y; Kawauchi S; Nakao M; Furuya T; Hashimoto K; Oga A; Oka M; Sasaki K
J Pathol; 2009 Apr; 217(5):677-84. PubMed ID: 19097070
[TBL] [Abstract][Full Text] [Related]
11. Gain of chromosome 8q: a potential prognostic marker in resectable adenocarcinoma of the pancreas?
Schleicher C; Poremba C; Wolters H; Schäfer KL; Senninger N; Colombo-Benkmann M
Ann Surg Oncol; 2007 Apr; 14(4):1327-35. PubMed ID: 17235717
[TBL] [Abstract][Full Text] [Related]
12. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
13. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
[TBL] [Abstract][Full Text] [Related]
14. 1p36 deletion is a marker for tumour dissemination in microsatellite stable stage II-III colon cancer.
Mayrhofer M; Kultima HG; Birgisson H; Sundström M; Mathot L; Edlund K; Viklund B; Sjöblom T; Botling J; Micke P; Påhlman L; Glimelius B; Isaksson A
BMC Cancer; 2014 Nov; 14():872. PubMed ID: 25420937
[TBL] [Abstract][Full Text] [Related]
15. Unexpected frequency of genomic alterations in histologically normal colonic tissue from colon cancer patients.
Conconi D; Redaelli S; Bovo G; Leone BE; Filippi E; Ambrosiani L; Cerrito MG; Grassilli E; Giovannoni R; Dalprà L; Lavitrano M
Tumour Biol; 2016 Oct; 37(10):13831-13842. PubMed ID: 27481518
[TBL] [Abstract][Full Text] [Related]
16. Microsatellite Alterations With Allelic Loss at 9p24.2 Signify Less-Aggressive Colorectal Cancer Metastasis.
Koi M; Garcia M; Choi C; Kim HR; Koike J; Hemmi H; Nagasaka T; Okugawa Y; Toiyama Y; Kitajima T; Imaoka H; Kusunoki M; Chen YH; Mukherjee B; Boland CR; Carethers JM
Gastroenterology; 2016 Apr; 150(4):944-55. PubMed ID: 26752111
[TBL] [Abstract][Full Text] [Related]
17. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
[TBL] [Abstract][Full Text] [Related]
18. Genetic aberrations in prostate carcinoma detected by comparative genomic hybridization and microsatellite analysis: association with progression and angiogenesis.
Strohmeyer DM; Berger AP; Moore DH; Bartsch G; Klocker H; Carroll PR; Loening SA; Jensen RH
Prostate; 2004 Apr; 59(1):43-58. PubMed ID: 14991865
[TBL] [Abstract][Full Text] [Related]
19. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator.
Ogunbiyi OA; Goodfellow PJ; Herfarth K; Gagliardi G; Swanson PE; Birnbaum EH; Read TE; Fleshman JW; Kodner IJ; Moley JF
J Clin Oncol; 1998 Feb; 16(2):427-33. PubMed ID: 9469325
[TBL] [Abstract][Full Text] [Related]
20. KRAS and aneusomy of chromosomes 4, 10 and 12 in colorectal carcinomas.
Beyer K; Altendorf-Hofmann A; Chen Y; Bickel K; Petersen I
Pathol Res Pract; 2015 Sep; 211(9):646-51. PubMed ID: 26122820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
